Ebrima Gibbs

947 total citations
31 papers, 627 citations indexed

About

Ebrima Gibbs is a scholar working on Neurology, Molecular Biology and Physiology. According to data from OpenAlex, Ebrima Gibbs has authored 31 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Neurology, 11 papers in Molecular Biology and 11 papers in Physiology. Recurrent topics in Ebrima Gibbs's work include Alzheimer's disease research and treatments (11 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Multiple Sclerosis Research Studies (7 papers). Ebrima Gibbs is often cited by papers focused on Alzheimer's disease research and treatments (11 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Multiple Sclerosis Research Studies (7 papers). Ebrima Gibbs collaborates with scholars based in Canada, Slovakia and United States. Ebrima Gibbs's co-authors include Neil R. Cashman, Joël Oger, Steven S. Plotkin, Masoud Yousefi, David S. Wishart, Leslie I. Grad, Edward Pokrishevsky, Valentyna Semenchenko, Anat Yanai and Megan A. O’Neill and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Scientific Reports.

In The Last Decade

Ebrima Gibbs

29 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ebrima Gibbs Canada 13 282 254 159 112 90 31 627
Wissam Beaino Netherlands 18 91 0.3× 224 0.9× 90 0.6× 145 1.3× 56 0.6× 46 916
S. Yano Japan 10 185 0.7× 210 0.8× 57 0.4× 61 0.5× 56 0.6× 15 707
Stefan Pursche Germany 10 307 1.1× 192 0.8× 60 0.4× 88 0.8× 37 0.4× 12 955
Jill A. Opsahl Norway 11 78 0.3× 284 1.1× 108 0.7× 53 0.5× 111 1.2× 13 544
Jacques Brotchi Belgium 12 97 0.3× 218 0.9× 39 0.2× 73 0.7× 50 0.6× 24 648
Foudil Lamari France 14 109 0.4× 257 1.0× 227 1.4× 78 0.7× 15 0.2× 28 582
Marie Bojsen‐Møller Denmark 13 183 0.6× 304 1.2× 365 2.3× 89 0.8× 18 0.2× 25 733
Jürgen W. A. Sijbesma Netherlands 16 42 0.1× 231 0.9× 57 0.4× 52 0.5× 69 0.8× 41 586
Maria Podbielska Poland 16 37 0.1× 331 1.3× 77 0.5× 80 0.7× 134 1.5× 20 599
Viktoria Ruf Germany 15 279 1.0× 222 0.9× 176 1.1× 96 0.9× 12 0.1× 47 786

Countries citing papers authored by Ebrima Gibbs

Since Specialization
Citations

This map shows the geographic impact of Ebrima Gibbs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ebrima Gibbs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ebrima Gibbs more than expected).

Fields of papers citing papers by Ebrima Gibbs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ebrima Gibbs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ebrima Gibbs. The network helps show where Ebrima Gibbs may publish in the future.

Co-authorship network of co-authors of Ebrima Gibbs

This figure shows the co-authorship network connecting the top 25 collaborators of Ebrima Gibbs. A scholar is included among the top collaborators of Ebrima Gibbs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ebrima Gibbs. Ebrima Gibbs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaplan, Johanne, Ebrima Gibbs, Beibei Zhao, et al.. (2025). Relationship between efficacy and preferential targeting of soluble Aβ aggregates. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(4). e70184–e70184.
2.
Gibbs, Ebrima, et al.. (2023). De Novo Design of a β-Helix Tau Protein Scaffold: An Oligomer-Selective Vaccine Immunogen Candidate for Alzheimer’s Disease. ACS Chemical Neuroscience. 14(15). 2603–2617. 3 indexed citations
3.
Fan, Xuelai, Esther del Cid‐Pellitero, Ebrima Gibbs, et al.. (2021). Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models. Communications Biology. 4(1). 232–232. 22 indexed citations
4.
Gibbs, Ebrima, et al.. (2021). A method for systematically ranking therapeutic drug candidates using multiple uncertain screening criteria. Statistical Methods in Medical Research. 30(6). 1502–1522. 6 indexed citations
5.
Gibbs, Ebrima, Ana Márquez, Soren Gantt, et al.. (2021). A novel multiplex electrochemiluminescent immunoassay for detection and quantification of anti-SARS-CoV-2 IgG and anti-seasonal endemic human coronavirus IgG. Journal of Clinical Virology. 146. 105050–105050. 14 indexed citations
6.
Thebault, Simon, Ebrima Gibbs, Pierre R. Bourque, et al.. (2021). MuSK not MNGIE: Atypical MuSK-antibody myasthenia presenting as a genetic disorder. Neuromuscular Disorders. 31(12). 1279–1281.
7.
Ladner-Keay, Carol L., Jie Lu, Judith M. Silverman, et al.. (2020). Molecular interactions between monoclonal oligomer-specific antibody 5E3 and its amyloid beta cognates. PLoS ONE. 15(5). e0232266–e0232266. 1 indexed citations
8.
Zhao, Beibei, et al.. (2019). Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1. Vaccine. 37(35). 4920–4927. 21 indexed citations
9.
Gibbs, Ebrima, Judith M. Silverman, Beibei Zhao, et al.. (2019). A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease. Scientific Reports. 9(1). 9870–9870. 36 indexed citations
10.
Cheng, Wai Hang, Kris M. Martens, Asma Bashir, et al.. (2019). CHIMERA repetitive mild traumatic brain injury induces chronic behavioural and neuropathological phenotypes in wild-type and APP/PS1 mice. Alzheimer s Research & Therapy. 11(1). 6–6. 47 indexed citations
11.
Gibbs, Ebrima, et al.. (2018). Computational Epitope Prediction and Screening Precision Antibody Therapeutics for Alzheimer's Disease. Biophysical Journal. 114(3). 674a–674a. 1 indexed citations
12.
Robert, Jérôme, Emily B. Button, Sophie Stukas, et al.. (2017). High-density lipoproteins suppress Aβ-induced PBMC adhesion to human endothelial cells in bioengineered vessels and in monoculture. Molecular Neurodegeneration. 12(1). 60–60. 44 indexed citations
13.
14.
Pérez, Rolando, Trent C. Bjorndahl, Mark Berjanskii, et al.. (2011). The prion protein binds thiamine. FEBS Journal. 278(21). 4002–4014. 26 indexed citations
15.
Farrell, Rachel, Tariq Aziz, Ebrima Gibbs, et al.. (2008). Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNβ in multiple sclerosis patients. Journal of Immunological Methods. 336(2). 113–118. 37 indexed citations
16.
17.
Boz, Cavit, Joël Oger, Ebrima Gibbs, & Sidney E. Grossberg. (2007). Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Multiple Sclerosis Journal. 13(9). 1127–1137. 34 indexed citations
18.
Gibbs, Ebrima & Joël Oger. (2007). The IgG subclass-specificities of anti-IFNβ antibodies change with time and differ between the IFNβ products in relapsing remitting multiple sclerosis patients. Journal of Neuroimmunology. 190(1-2). 146–150. 12 indexed citations
19.
Gibbs, Ebrima, et al.. (2006). During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. Journal of Neuroimmunology. 177(1-2). 161–166. 36 indexed citations
20.
Oger, Joël & Ebrima Gibbs. (2006). Should neutralizing antibodies be monitored during interferon-β treatment for multiple sclerosis?. Nature Clinical Practice Neurology. 2(2). 76–77. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wissam Beaino Breakdown of academic impact, for papers by S. Yano Breakdown of academic impact, for papers by Stefan Pursche Breakdown of academic impact, for papers by Jill A. Opsahl Breakdown of academic impact, for papers by Jacques Brotchi Breakdown of academic impact, for papers by Foudil Lamari Breakdown of academic impact, for papers by Marie Bojsen‐Møller Breakdown of academic impact, for papers by Jürgen W. A. Sijbesma Breakdown of academic impact, for papers by Maria Podbielska Breakdown of academic impact, for papers by Viktoria Ruf
Rankless by CCL
2026